V
Vir Biotechnology
Brings together cutting-edge innovations with scientific expertise and management
At a glance
- Status
- Listed
- Listing
- IPO 2019
Open roles
Vir Biotechnology in the San Francisco ecosystem
The Vir Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later7 investors entered at this stage
ARCH Venture Partners- OUOregon Health & Science University
SoftBank Vision Fund- AVAltitude Life Science Ventures
- APAlta Partners
- BFBill & Melinda Gates Foundation
8VC
Source: Dealroom Talent Intelligence.
Patents
86 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Investments and acquisitions
Disclosed deals where Vir Biotechnology was the backer or acquirer, 2017–2023. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.
5 deals across Vir Biotechnology's capital deployment.
Where the deals concentrate by sector, stage, and decade.
Vir Biotechnology's portfolio, mapped.
See Vir Biotechnology on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
Vir Biotechnology raises $150M in stock offering ahead of key trials
Vir's chronic hepatitis delta combo hits all endpoints in pivotal Phase 3 trial
Man Group takes new $1.5M stake in Vir Biotechnology
